David S Nelson
Overview
Explore the profile of David S Nelson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta P, Li L, Singh D, Nova S, Arias-Mendoza F, Orlovskiy S, et al.
Acad Radiol
. 2025 Feb;
PMID: 39984334
Rationale And Objectives: Melanoma, an aggressive skin cancer, often harbors BRAFV600E mutations driving tumor progression via the mitogen-activated protein kinase (MAPK) pathway. While targeted therapies like BRAF (dabrafenib) and MEK...
2.
Orlovskiy S, Gupta P, Arias-Mendoza F, Singh D, Nova S, Nelson D, et al.
Int J Mol Sci
. 2025 Jan;
26(2).
PMID: 39859224
Radiation therapy (RT) is the cornerstone treatment for prostate cancer; however, it frequently induces gastrointestinal and genitourinary toxicities that substantially diminish the patients' quality of life. While many individuals experience...
3.
Gupta P, Orlovskiy S, Arias-Mendoza F, Nelson D, Nath K
Cells
. 2024 Jul;
13(14.
PMID: 39056801
The MAPK signaling pathway with mutations has been shown to drive the pathogenesis of 40-60% of melanomas. Inhibitors of this pathway's BRAF and MEK components are currently used to treat...
4.
Nath K, Gupta P, Basappa J, Wang S, Sen N, Lobello C, et al.
J Transl Med
. 2024 Jul;
22(1):622.
PMID: 38965536
Background: Inhibition of kinases is the ever-expanding therapeutic approach to various types of cancer. Typically, assessment of the treatment response is accomplished by standard, volumetric imaging procedures, performed weeks to...
5.
Orlovskiy S, Gupta P, Roman J, Arias-Mendoza F, Nelson D, Koch C, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611062
Prostate cancer is a multi-focal disease that can be treated using surgery, radiation, androgen deprivation, and chemotherapy, depending on its presentation. Standard dose-escalated radiation therapy (RT) in the range of...
6.
Gupta P, Orlovskiy S, Arias-Mendoza F, Nelson D, Osborne A, Pickup S, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254853
Dabrafenib therapy for metastatic melanoma focuses on blocking growth-promoting signals produced by a hyperactive BRAF protein. We report the metabolic differences of four human melanoma cell lines with diverse responses...
7.
Gupta P, Orlovskiy S, Roman J, Pickup S, Nelson D, Glickson J, et al.
RSC Adv
. 2023 Jul;
13(29):19813-19816.
PMID: 37404315
Lonidamine (LND) is an anti-cancer drug with great potential as a metabolic modulator of chemotherapy, radiotherapy, hyperthermia, and photodynamic therapy in cancer treatment. LND affects several important aspects of cancer...
8.
Shestov A, Nath K, Nelson D, Wasik M, Glickson J
NMR Biomed
. 2022 Feb;
36(4):e4716.
PMID: 35196744
Bonded cumomers are sets of isotopomers of C-labeled metabolites containing a particular sequence of contiguously or singly labeled carbon atoms. Only these isotopomers contribute to multiplet structure in the C...
9.
Nelson D, Marano R, Joo Y, Tian S, Patel B, Kaplan D, et al.
PLoS One
. 2019 Sep;
14(9):e0222400.
PMID: 31527903
Langerhans cell histiocytosis (LCH) is characterized by the accumulation of Langerin (CD207)-expressing histiocytes. Mutational activation of mitogen-activated protein kinase pathway genes, in particular BRAF, drives most cases. To test whether...
10.
Lee S, Shestov A, Guo L, Zhang Q, Roman J, Liu X, et al.
Mol Cancer Res
. 2019 Mar;
17(6):1365-1377.
PMID: 30862686
Current methods to evaluate effects of kinase inhibitors in cancer are suboptimal. Analysis of changes in cancer metabolism in response to the inhibitors creates an opportunity for better understanding of...